Form 4 for RAPP Rapport Therapeutics, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001193125-26-059883 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-02-19 | 2026-02-17 | RAPP | Bredt David | CSO | S - Sale+OE | $29.02 | -8,500 | 394.7K | -2% | -$246.6K |
| DT | 2026-02-19 | 2026-02-19 | RAPP | Bredt David | CSO | M - OptEx | $1.80 | +6,000 | 393.1K | +2% | +$10.8K |
| DT | 2026-02-19 | 2026-02-19 | RAPP | Bredt David | CSO | M - OptEx | $0.00 | -6,000 | 88.1K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 2,200 | $29.59 | 387,075 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 2 | Common | Common Stock | 2026-02-17 | S | D | 5,400 | $28.95 | 389,275 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 3 | Common | Common Stock | 2026-02-17 | S | D | 900 | $28.02 | 394,675 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 4 | Common | Common Stock | 2026-02-19 | M | A | 6,000 | $1.80 | 393,075 | D | — | — | |
| 5 | Derivative | Stock Options (Right to Buy) | 2026-02-19 | M | D | 6,000 | $0.00 | 88,080 | D | $1.80 · — to 2033-12-05 | 6,000 Common Stock | (F6) 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |